Search research articles
Contact Us
Filters
Showing results (521-530 of 540) with videos related to
Page
of 54
Sort By:
The Lancet. Infectious Diseases
|
July 8, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
Gary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, et al.
Emerging Infectious Diseases
|
July 1, 2021
Predictors of Nonseroconversion after SARS-CoV-2 Infection
Weimin Liu, Ronnie M Russell, Frederic Bibollet-Ruche, et al.
Nature Communications
|
March 23, 2024
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Daniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Communications
|
December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Daniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
The Journal of Experimental Medicine
|
October 12, 2011
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated
Hua-Xin Liao, Xi Chen, Supriya Munshaw, et al.
Nature Medicine
|
September 8, 2020
Recommendations for measuring HIV reservoir size in cure-directed clinical trials
Mohamed Abdel-Mohsen, Douglas Richman, Robert F Siliciano, et al.
The Lancet. HIV
|
February 26, 2026
Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials
Thumbi Ndung'u, Krista L Dong, Donn J Colby, et al.
The Journal of Experimental Medicine
|
June 3, 2009
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
Jesus F Salazar-Gonzalez, Maria G Salazar, Brandon F Keele, et al.
Science Translational Medicine
|
January 14, 2021
Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption
Marcos V P Gondim, Scott Sherrill-Mix, Frederic Bibollet-Ruche, et al.
JAMA Network Open
|
January 25, 2022
Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma
Hyung Park, Thaddeus Tarpey, Mengling Liu, et al.
Page
of 54
Search research articles
Search
Showing results (521-530 of 540) with videos related to
Sort By:
Page
of 54
The Lancet. Infectious Diseases
|
July 8, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
Gary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, et al.
Emerging Infectious Diseases
|
July 1, 2021
Predictors of Nonseroconversion after SARS-CoV-2 Infection
Weimin Liu, Ronnie M Russell, Frederic Bibollet-Ruche, et al.
Nature Communications
|
March 23, 2024
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Daniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Communications
|
December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Daniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
The Journal of Experimental Medicine
|
October 12, 2011
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated
Hua-Xin Liao, Xi Chen, Supriya Munshaw, et al.
Nature Medicine
|
September 8, 2020
Recommendations for measuring HIV reservoir size in cure-directed clinical trials
Mohamed Abdel-Mohsen, Douglas Richman, Robert F Siliciano, et al.
The Lancet. HIV
|
February 26, 2026
Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials
Thumbi Ndung'u, Krista L Dong, Donn J Colby, et al.
The Journal of Experimental Medicine
|
June 3, 2009
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
Jesus F Salazar-Gonzalez, Maria G Salazar, Brandon F Keele, et al.
Science Translational Medicine
|
January 14, 2021
Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption
Marcos V P Gondim, Scott Sherrill-Mix, Frederic Bibollet-Ruche, et al.
JAMA Network Open
|
January 25, 2022
Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma
Hyung Park, Thaddeus Tarpey, Mengling Liu, et al.
Page
of 54